Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug,... see more

GREY:ATBPF - Post Discussion

View:
Post by hammerman15 on Nov 26, 2020 3:23pm

Strategic Exit?

Dan mentioned a strategic exit of otena.... Does that mean a buyout just for otena ? And then Antibe is out completely on anything otena in the future? Assuming it would be a few billion would that equate to that much in market cap?
Comment by Tricks on Nov 26, 2020 3:30pm
How would anyone on this board know?
Comment by IrishCanuck on Nov 26, 2020 3:46pm
Correct, you can buy Otena without buying the company and ATE loses all future rights to it, or we could sell it but retain royalties. There are a thousand business deals that could be structured. Pharma could buy ATE or just Otena and leave other IP intact. Both would make the share price go up 1) If we sold Otena then ATE gets cash and retains IP. That way the market value of each share is more ...more  
Comment by hammerman15 on Nov 26, 2020 3:54pm
Thanks Canuck! Knowing the future earning potential for otena I assume they wouldn't be letting it go for anything less than a few billion! This is my first biotech but own 126k shares so excited for what may happen! When in doubt trust the science.
Comment by MrMugsy on Nov 26, 2020 4:50pm
All fair comments. I believe Dan is working to get this thing to a billion dollar valuation ... that's likely the immediate goal w.r.t. the the immediate strategy. We know ATE is looking at any and every potential deal. They will take a partnership for the 1st drug ... and ... the higher the initial payout, the lower the royalty payment.  We also know they would consider a full buyout ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities